Sage Therapeutics Inc (NAS:SAGE)
$ 11.09 0.46 (4.31%) Market Cap: 667.42 Mil Enterprise Value: -72.17 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 46/100

SAGE Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 06:30PM GMT
Release Date Price: $40.75 (+2.31%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Al-righty. Let's go ahead and get started. Welcome, everybody, to the Tuesday morning of the JPMorgan Healthcare Conference -- 41st Annual JPMorgan Healthcare Conference.

My name is Anupam Rama, I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Malcolm Kuno and Priyanka Grover. The next presenting company is Sage. Presenting on behalf of the company, we have CEO, Barry Greene. Barry?

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Thanks, Anupam, and squad. And thanks for the organizers of JPMorgan for having us here today. It's great to be here live in sunny San Francisco, live again. I'm Barry Greene, as Anupam said, the CEO of Sage Therapeutics.

It's an absolute pleasure to provide an update on the extraordinary progress that we at Sage are making, progressing a pipeline of novel brain health medicines. I will be making forward-looking statements.

As we stand here as an industry, we can be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot